3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Genitourinary
2
Dermatologic
2
Thoracic
1
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
CNS
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
Cisplatin
98
pembrolizumab
79
Radiotherapy
49
Carboplatin
41
Magnetic Resonance Spectroscopy
37
toripalimab
34
Radiotherapy, Intensity-Modulated
34
Gemcitabine
29
Docetaxel
28
Cetuximab
28
Specimen Handling
26
Surgical Procedures, Operative
23
Paclitaxel
23
Fluorouracil
22
Radiation
20
Nivolumab
20
Biopsy
18
Drug Therapy
17
Chemoradiotherapy
17
Blood Specimen Collection
17
Capecitabine
15
Surveys and Questionnaires
14
Standard of Care
14
tislelizumab
13
Platinum
13
camrelizumab
12
nimotuzumab
11
Immune Checkpoint Inhibitors
11
130-nm albumin-bound paclitaxel
11
1,2-diaminocyclohexaneplatinum II citrate
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Solutions
×
Head & Neck
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled